

# Index

- Absence seizures, 530  
Acetylcholine, as CNS neurotransmitter, 558  
Acetylcholine receptors  
  antagonists, 572  
  in limbic thalamus, 29, 87  
  role in NMDA antagonist neurotoxicity, 567–568  
Acetylcholinesterase, 78  
  in cingulate cortex, 167–170  
  in thalamocortical axons, 133  
 $\alpha$  Adrenoceptors  
  in cingulate cortex, 291–292  
  postsynaptic, 293–294  
  in limbic thalamus, 84  
 $\beta$  Adrenoceptors  
  in Alzheimer's disease, 63  
  in cingulate cortex, 84  
  postsynaptic, 293–294  
  in thalamocortical axons, 136–137  
Afferent development, in cingulate cortex, 162–172  
Age  
  effects on learning and memory, 137–139  
  effects on thalamocortical circuit, 137–139  
Agranular motor cortex, cingulate cortex connections of, 261–263  
Akinetic mutism syndrome,  
  from cingulate lesions, 435, 535, 536–537, 545–546, 585–586  
ALZ-50, immunoreactivity, 175  
  neuronal death, 172–173  
Alzheimer's disease  
   $\beta$ -adrenoceptor binding, 63  
  amyloid deposits, 606–607  
calcium-binding proteins, 199–202  
cingulate cortex role in, 302–303  
CNS serotonergic and noradrenergic system dysfunction, 302–303  
cysteine metabolism  
  disturbance, 575  
hippocampal-to-cingulate cortex projection role in, 242  
HSP gene induction and, 565  
involvement of  
  hippocampal formation, 608  
  limbic thalamus, 145, 606–626  
  mamillary body, 608–609  
  presubiculum region, 617  
limbic circuits and, 606–626  
muscarinic receptors, 63  
muscimol binding to receptors, 62  
neuritic plaques, 582  
neurofibrillary tangles, 607, 608, 618–621  
neuron degeneration, 60–64  
neuropathology, 582, 606–607  
  stages, 618–621  
possible excitotoxin role in, 562  
subtype approach to studies of, 64  
transmitter receptors in cingulate cortex, 20, 51  
 $\alpha$ -Amino adipate, as excitatory amino acid antagonist, 559  
 $\gamma$ -Aminobutyric acid. *See* GABA  
2-Amino-4-phosphonobutyric acid. *See* AP4  
D-Amino-5-phosphonopentanoic acid. *See* D-AP5  
2-Amino-3-phosphonopropionic acid. *See* AP3  
D-2-Amino-5-phosphonovalerate, as excitatory amino acid antagonist, 559  
Amnesia  
  from cingulate lesions, 547  
  from hippocampal lesions, 546  
  retrosplenial, 547–548  
  Wernicke-Korsakoff syndrome, 548–549  
AMPA receptors, in cingulate cortex, 559  
Amygdala  
  cingulate cortex connections with, 252–254  
Amygdalar division, of limbic system, 11  
Amygdalothalamic pathway, 80–81  
Amyloid deposits, as Alzheimer's disease symptom, 606–607, 618  
entorhinal cortex, 618  
hippocampal formation, 608  
limbic thalamus, 609–610  
mamillary body, 608  
retrosplenial region and supracallosal cortex, 614  
Amyotrophic lateral sclerosis, possible excitotoxin role in, 562  
Annexins, as calcium-binding proteins, 181  
Anterior cerebral artery, 23, 535  
Anterior cingulate cortex  
  anatomical organization, 351–355  
  contributions to attention, 540

- behavioral control and spatial memory, 360–361, 435  
 emotion, 211–214, 217–219  
 noxious stimuli responses, 323–334  
 visceral control, 209–211  
 vocalization, 332  
 cytoarchitecture, 25–26, 206–211  
   in schizophrenia, 589–590  
 dorsal and ventral systems, 207  
 efferents from, 209–211, 282  
 electrically evoked responses, 381–382, 447–448  
 inferior parietal region connections with, 587  
 lesion studies on, 450, 452–453  
 limbic system and, 355  
 medial thalamic projections to, 320–323  
 NMDA receptors in, 559, 560, 563  
 in rat, 206–222  
 in schizophrenia, 589–594  
   defective circuitry, 595–597  
 self-stimulation studies on reinforcement by, 451–452  
 somatic, ocular, and complex subregions of, 354–355, 359–360  
 subregional differences in cortical input, 348, 353–354  
 subregional differences in thalamic input, 354  
 topography, 448–450  
 training-induced neuronal studies of, 483–498  
**Anterior circuit**, of thalamocortical system, 479  
**Anterior principal nucleus**, 73  
**Anterodorsal nucleus**, 71  
   afferent innervation, 79–84  
   in Alzheimer's disease, 610, 621  
   cytoarchitecture, 73–74, 125–127  
   functional connections with hippocampal formation, 515  
   projections to retrosplenial cortex, 128  
   synaptology, 89–90  
**Anteromedial nucleus**, 19, 71  
   in Alzheimer's disease, 610  
   cytoarchitecture, 73, 609–610  
   parvocellular medial mamillary nucleus projections to, 609  
   projections to retrosplenial cortex, 127–128
- Anteroventral nucleus**, 71  
   in Alzheimer's disease, 610  
   cytoarchitecture, 73, 125–127  
   parvocellular medial mamillary nucleus projections to, 609  
   projections to retrosplenial cortex, 128  
   synaptology, 89–90  
**Anxiety disorder**, cingulate cortex lesions in improvement of, 535  
**Apathico-akinetico-abulic syndrome**, schizophrenia compared to, 585  
**AP3**, as receptor antagonist, 561–562, 575  
   binding characteristics of, 561–562  
**AP4** receptor binding, 559  
**Area 6**  
   cytoarchitecture, 424  
   role in motor activity, 435–436  
   surgical lesions of, 435  
**Area 23**  
   of cingulate cortex, 32, 38, 345, 348, 423, 424  
   damage effects on, 536  
   monoaminergic projections to, 286, 295, 303  
   noradrenergic afferents to, 291  
   pathological changes in Alzheimer's disease, 302–303  
**Area 23a**, calcium-binding proteins in, 185–187, 192–193  
**Area 23b**  
   calcium-binding proteins in, 185–187, 192–193, 194  
   projections of, 436  
**Area 23c**  
   calcium-binding proteins in, 185–187, 192–193  
   cytoarchitecture, 34, 424  
**Area 24**, 345, 423, 424  
   damage effects on, 461  
   development, 152  
   monoaminergic projections to, 285–286, 289, 295–296, 303  
   noradrenergic afferents in, 291  
   role in autonomic responses and vocalization, 434  
   role in motor functions, 297–298, 435–436  
   role in spatial memory, 466  
   surgical removal of, 535, 536  
**Area 24a**, calcium-binding proteins in, 185–187, 190–192  
**Area 24b**  
   calcium-binding proteins in, 185–187, 190–192, 199  
   nociceptive neurons in, 321–323, 325–330, 336, 337  
   projections of, 436  
   training-induced neuronal activity in, 492  
**Area 24c**  
   calcium-binding proteins in, 185–187, 190–192, 194, 199  
   cytoarchitecture, 424  
   in monkey, 35  
**Area 24c'**  
   in monkey, 35  
   as motor area, 276  
   parvalbumin-positive neurons in, 197  
**Area 25**, 32, 207, 253, 382, 448  
**Area 29**, 345, 348, 570  
   anterior thalamic connections of, 473–474, 475  
   calcium-binding proteins in, 187–189, 192–193  
   damage effects on, 466, 467, 469–471, 475  
   development, 152  
   fibers of passage and, 469–471  
   hippocampal connections of, 472–473, 476  
   monoaminergic projections to, 286, 289, 295, 303  
   noradrenergic afferents in, 291  
   of retrosplenial cortex, 36, 127  
   role in behavior, 461, 468  
   role in memory, 467, 475–476  
   role of subfields in spatial learning, 471–472  
   training-induced neuronal activity in, 493  
**Area 29a**, of retrosplenial cortex, 27, 127, 141  
**Area 29b**, of retrosplenial cortex, 27, 127, 141  
**Area 29c**  
   of retrosplenial cortex, 28, 127, 141  
   role in spatial memory, 471, 472  
**Area 29d**  
   of retrosplenial cortex, 30, 139–141  
   role in spatial memory, 471, 472  
**Area 29e**, of granular retrosplenial cortex, 30  
**Area 30**, 345, 348  
   calcium-binding proteins in, 187–189, 192–193  
   of granular retrosplenial cortex, 31

- monoaminergic projections to, 286, 303  
noradrenergic afferents in, 291  
of primate retrosplenial cortex, 36–37  
**Area 31**, 32, 38, 345, 348  
**Area 32**, surgical removal of, 537  
**Area 33**  
  calcium-binding proteins in, 190–192  
  in human cingulate cortex, 34  
**Area ectogenualis**, in human cingulate cortex, 34  
Arousal mechanisms, cingulate cortex role in, 298–300  
Arteries, of cingulate gyrus, 23–24  
Aspartate, as neurotoxin, 562  
Attention  
  cingulate cortex role in, 345, 539–542  
  covert shifts of, 372–374  
**Attentional deficit**  
  with cingulate lesions, 537  
  in schizophrenia, 584–585, 592, 595  
Automatic behavior, from cingulate cortex stimulation, 528–529  
Automatisms, in epilepsy, 7, 529, 531, 532, 533  
Autonomic function, 311–441  
  cingulothalamic and prefrontal control of, 381–414  
  classical conditioning of, 390–394  
  corticothalamic control of, 403–407  
  electrically evoked responses, 381–382  
  learned changes in, 390–403  
  neuronal correlates of, 389–390  
  pharmacology of, 388  
  training-induced modulation of, 384–386  
Autonomic information, thalamus contribution to, 105  
Autonomic-related responses, from electrically stimulated limbic lobe, 11  
Autoreceptors  
  for norepinephrine, 293  
  for serotonin, 287–289  
Avoidance learning  
  cholinergic system role in, 336  
  cingulate cortex role in, 285, 300–301, 314  
  cingulectomy effects on, 324–325  
lesion studies in, 479–480, 485–488  
model system for, 478–523  
theoretical model of circuitry and information flow in, 518  
unit recording studies, 480–481  
**Axon terminals of limbic thalamus**  
  acetylcholine receptors in, 29  
  distribution of, 127–130  
  morphology of, 130–133  
**Calbindin D-28k**  
  in Alzheimer's disease, 200–201  
  biochemistry and distribution, 182  
  in cingulate cortex, 184–195  
  in limbic thalamus, 97–98  
  neuronal localization, 182–184  
**Calcium-binding proteins**. *See also* Calbindin D-28k; Calretinin; Parvalbumin  
  in Alzheimer's disease, 199–202  
  in cingulate cortex, 181–205  
  functional implications, 195–202  
  interspecies comparison, 193–195  
  in limbic thalamus, 97–98  
  as markers for neuron subsets, 195–196  
**Barbiturates**  
  effect on GABA receptors, 569  
  neuroprotective action against NMDA antagonists, 568  
**Basal forebrain**  
  projections to cingulate cortex, 237, 239–240  
  projections to limbic thalamus, 86–87  
**Basal ganglia**, input from anterior cingulate cortex, 208–209  
**Behavior**  
  cingulate cortex role in, 331, 345, 527–556  
  anterior and posterior areas compared, 360–361  
  corticothalamic control of, 403–407  
  of humans, 527–556  
  initiation-activation of, 542–546  
  limbic thalamus role in, 106, 109  
  overlapping abnormalities of, in psychiatric disorders, 598–600  
  relevance of duration-related neuronal activity to, 493–495  
**Behavioral tasks**  
  cerebral blood flow studies in relation to, 433  
  single-unit activity in relation to, 432–433  
**Benzodiazepines**  
  neuroprotective action against NMDA antagonists, 568  
  receptors for, 93  
**Bipolar disorder**, behavioral abnormality in, 598–599, 600  
**Body movements**, evoked by intracortical stimulation, summary maps, 430  
**Bursting neurons**, regular-spiking neurons compared to, 42  
**Callosom marginal artery**, 24  
**Calretinin**  
  biochemistry and distribution, 182  
  in cingulate cortex, 184–195  
  neuronal localization, 182–184  
**Candidate inhibitory neurons**, in cingulate cortex, 230–233  
**3-[ $(\pm)$ -2-Carboxypiperazine-4-yl]-propyl-1-phosphonic acid.**  
  *See* CPP  
**Cat**, cingulate cortex, 345–365  
**Cat-301 membrane antigen**, in limbic thalamus, 98  
**Central concept of emotion**, 217–218  
**Central medial nucleus**, anatomy, 609–610  
**Cerebral blood flow** in humans, factors affecting, 425, 433, 540, 543  
**c-fos protein**, expression of, 564, 565  
**Cholecystokinin**  
  neurons immunoreactive to, in cingulate cortex, 158, 160  
  thalamic fibers containing, 85  
**Choline acetyltransferase**  
  cingulate bipolar neurons, 570–571  
  in limbic thalamus fibers, 87  
**Cholinergic afferents**  
  development in cingulate cortex, 167–170  
  of limbic thalamus, 87  
**Cholinergic system**  
  in avoidance learning, 314  
  in mediation of neurotoxic effects, 557

- in noxious stimuli responses, 334–336
- Cingulate cortex**, 71  
  agranular, 25  
    motor cortex connections of, 261–263  
  in Alzheimer's disease, 302–303  
  anterior. *See* Anterior cingulate cortex  
  calcium-binding proteins in, 181–205  
  of cat, 345–365  
  conditioned stimulus probability studies on, 495–497  
  connections of  
    with amygdala, 232–234  
    cingulostriate, 273–274  
    corticocortical, 270–272  
    frontal lobe, 258–263  
    functional significance, 276–278  
    with insula, 264  
    intracingulate, 266–270  
    orbitofrontal, 260–261  
    parahippocampal, 254–255  
    with parietal lobe, 263–264  
    with temporal pole, 257–258  
  contributions to  
    attention, 345, 539–542  
    avoidance conditioning, 285, 300–301  
    human behavior, 527–556  
    limbic system, 1–15  
  limbic thalamic  
    training-induced neuronal activity, 503–512  
  motor activity, 331, 529, 542  
  orientation and arousal mechanisms, 298–300  
  pain responses, 313–344  
  reinforcement, 445–460  
  sensorimotor and autonomic responses, 345–365  
  cytoarchitectonic development, 156–157  
  development, 151–180  
  in disease, 544, 545, 547  
  dopaminergic system in, 294–295  
  dysgranular, 25, 345  
  electrical stimulation of  
    autonomic changes from, 528  
    primitive automatic behaviors from, 528–529  
  glutaminergic system in, 557  
  granular, 25, 347  
  hippocampal connections with, 254  
  functional implications, 241–244
- integration with other CNS inputs, 235–237  
  lesions of, 527, 540–541, 545–546  
    in conditioned bradycardia studies, 394  
    in humans, 534–539  
  mechanisms of reinforcement in, 445–460  
  metabolic mapping studies, 452–454  
  midline visceromotor cortex and, 360  
  of monkey, 249–284  
  monoaminergic control of efferent projections of, 297  
  monoaminergic innervation of, 285–310  
  monoaminergic regulation of afferents to, 296–297  
  motor areas. *See* Cingulate motor areas  
  motor system interactions of, 249–251  
  neuronal changes in, during training, 396–397  
  neuronal circuits and transmitters of, 240  
  neuronogenesis in, 157–158  
  neurophysiological studies on, 227–234  
  NMDA antagonist neurotoxic effects on, 565–568  
  NMDA receptors in, 559  
  noradrenergic system in, 290–294  
  opioid receptor regulation of pyramidal neurons of, 332–334  
  posterior. *See* Posterior cingulate cortex  
  of primates, 32–38  
  projections of  
    anatomical studies, 225–227  
    cingulopontine, 275–276  
    cingulorubral, 274–275  
    to limbic thalamus, 78–79, 99–105, 108  
  of rat, 224–248  
  receptor localization, 51–53  
  role in Gilles de la Tourette syndrome, 544–545  
  in schizophrenia, 574–575, 581–605  
  seizures arising in, 529–534  
  sensory cortex comparison to, 152  
  serotonergic system in, 286–290  
  structural organization, 19–70  
  superior temporal cortex connections with, 255–257
- synaptic plasticity in, 233–234  
  synaptology of, 228–234  
  temporal lobe connections of, 252–258  
  thalamic projections to, 72, 235–240  
  transient developmental protein expression, 174–175  
  vocalization region of, 331–332
- Cingulate gyrus**  
  arteries, 23–24  
  caudomedial lobule, 21  
  cingulate motor area, 427–428  
  cingulate sulcus, 21  
  contributions to  
    emotion and autonomic function, 415  
    skeletomotor function, 433–436  
    vocalization, 436  
  cytoarchitecture, 36, 345  
  hippocampal formation relationship with, 278  
  infarcts of, behavioral and attentional changes from, 584, 585  
  isthmus, 21  
  marginal ramus, 21  
  of monkey, 36  
  splenial sulcus, 21
- Cingulate motor areas**, 415–441  
  connections of, 270–277  
  cortical inputs to, 277, 426–428  
  summary diagram, 427
- corticospinal neuron origin in, 420–423  
  cytoarchitecture, 423–425  
  electrical stimulation of, 428–431  
  identification, 417–420  
  physiological studies, 428–433  
  thalamic inputs to, 425–426
- Cingulate sulcus**  
  anatomical reconstruction, 415–417  
  corticospinal neurons from cortex in, 420  
  cytoarchitecture of areas in, 423–425, 436  
  of monkeys and humans, 34–35  
  motor areas in, 415, 428, 436
- Cingulectomy**  
  in animals, effect on avoidance learning, 324–325  
  in humans, for psychiatric disorders, 528, 537–538
- Cinguloperaqueductal gray connection**, role in noxious stimuli response, 331

- Cingulothalamic control, of autonomic function, 381–414
- Cingulothalamic projections, role in noxious stimuli responses, 330–331
- Cingulotomy  
for depression alleviation, 285, 599  
for pain relief, 285, 323–324, 539
- Cingulum bundle  
lesions of, 538, 545  
neuroanatomy, 24–25
- Cingulotomy, 24–25, 538–539  
for Gilles de la Tourette syndrome, 24–25, 538–539  
for pain alleviation, 323–324  
for psychiatric disorders, 538
- Circumventricular organ, glutamate-induced lesions in, 558
- Claustrum, cingulate cortex connections of, 264–266
- Cocaine  
dopamine depletion effects on use of, 455  
reinforcement studies using metabolic mapping, 455–456
- Cognition  
abnormalities of  
in Alzheimer's disease, 621  
in schizophrenia, 586–587  
memory and, 10
- Conditioned bradycardia, 393  
biological relevance of, 406–407  
in studies of cingulate lesions, 394–396
- Conditioned stimulus duration, in studies of avoidance learning, 492–495
- Conditioned stimulus probability, in studies of avoidance learning, 495–498
- Configural association system, hippocampal formation role in, 474
- Connection model of medial pain system, 336–338
- Contralateral projections of granular retrosplenial cortex, 28
- Cortical inputs to cingulate motor areas, 426–428
- Cortical transition, retrosplenial cortex and, 35–36
- Corticospinal neurons  
origin in cingulate motor areas, 420  
topographic organization, 422–423
- Corticothalamic organization, 125  
topography, 143
- Corticothalamic projections, 139–142
- CPP, as competitive NMDA antagonist, 565, 567, 568
- Crossed lesion approach, in spatial memory studies, 472–473, 474
- Crying, clinical findings on, 10–11
- Cyanopindolol, use in receptor localization, 59, 63
- L-Cysteine, brain sensitivity to, 57
- Cytoarchitecture  
of cingulate cortex, 19, 25–38  
of limbic thalamus, 73–78, 125–127
- Cytochrome oxidase, in thalamocortical axons, 133
- D-AP5, as competitive NMDA antagonist, 565
- DARPP-32, in rat cingulate cortex, 79, 198
- "Death program" hypothesis for neurons, 173
- Dementia pugilistica, possible excitotoxin role in, 562
- Dendritic bundles, in retrosplenial cortex, 129–130
- Depression  
amelioration by cingulotomy, 285, 599  
behavioral abnormality in, 599  
cingulate cortex lesions in improvement of, 535, 599  
dysfunction of cerebral monoaminergic systems in, 301–302, 303
- Diazepam  
effect on GABA receptors, 569  
use to prevent ketamine side effects, 568
- Di-I, use in axonal connection studies, 163
- Diisopropyl fluorophosphate, use in receptor localization, 58
- Directional evolution of limbic system, 8
- Discriminative avoidance learning model system for, 478–523  
theoretical model of circuitry and information flow in, 518
- Distal arm representations, of cingulate motor areas, 423
- Docility, with cingulate lesions, 537
- Dopamine  
function in cingulate cortex and limbic system, 285–286  
role in cocaine  
self-administration, 455  
role in cortical self-stimulation, 450–451
- Dopamine afferents  
in cingulate cortex, 294  
development in cingulate cortex, 164–165
- Dopamine receptor blockers, use in mania and schizophrenia therapy, 600
- Dopamine receptors, in cingulate cortex, 294–295
- Dopaminergic system, in cingulate cortex, 294–295, 544, 545
- Dorsal motor nucleus of the vagus, anterior cingulate cortex projections to, 382
- Down's syndrome, calcium-binding proteins in, 201
- Drinking, anterior cingulate cortex role in, 214–215
- Drug self-administration, use in brain circuit studies of reinforcement, 454–457
- Dynorphin, thalamic fibers containing, 85
- EF-hand proteins, as calcium-binding proteins, 181
- Electrical stimulation  
of cingulate motor areas, 428–431  
of medial thalamic nuclei, for pain relief, 319
- Emergence reactions, to ketamine, 568
- Emotion  
anterior cingulate cortex role in, 211–214, 217–219, 285, 435  
basic affects of, 7  
cerebral histaminergic systems and, 85  
general affects of, 7  
James-Lange theory of, 407  
limbic system role in, 5–6, 7, 11–13, 711, 106–107  
peripheral and sensory concepts of, 217–218  
specific affects of, 7  
visceral, 6–7

- Emotional blunting  
from cingulotomy, 536  
in schizophrenia, 583–584
- $\beta$ -Endorphin, thalamic fibers containing, 85
- Enkephalin  
thalamic fibers containing, 85  
use in receptor localization in cingulate cortex, 56
- Entorhinal cortex  
cytoarchitecture, 617  
projections to cingulate cortex, 226–227, 228–230
- Epilepsy  
absence seizures in, 530  
depth electrode recordings in, 530–531  
limbic system and, 6, 7  
possible excitotoxin role in, 562  
postictal automatisms in, 529  
primary generalized, 532  
psychomotor, 6, 7
- Error registration, cingulate cortex role in, 345
- Ethanol, prenatal effect on cingulate neuronogenesis, 159
- Event holding, layer I role in, 20
- Event-processing system, 517–519
- Excitatory amino acids  
in central nervous system, 557  
in limbic thalamus, 95–96  
receptors for, 559–560
- Excitotoxins  
role in neurodegenerative disorders, 562  
use in receptor localization, 52
- Family-related behavior, 10, 12–13. *See also* Maternal behavior; Playful behavior; Separation cry
- Fasciculus cinguli.* *See* Cingulum bundle
- Finger movements, cingulate sulcus neurons related to, 433
- “Flashbulb” memories, 407
- Flat affect, in schizophrenia, 243, 583
- Forelimb representations, of cingulate motor areas, 422–423
- Frontal lobe  
cingulate cortex connections with, 258–263  
primary motor cortex and pre-motor areas in, 426–427
- Frontopolar artery, 24
- GABA  
as inhibitory neurotransmitter  
in thalamus, 92  
neurons immunoreactive to, 88  
in cingulate cortex, 158–160  
transmission in schizophrenic anterior cingulate cortex, 590–592
- GABAergic inhibitory neurons  
in cingulate cortex, 230–233  
in limbic thalamus, 92–93
- GABAergic systems, 86  
in layer Ia, 54  
muscimol binding of receptors in cingulate cortex, 54, 62  
neurons immunoreactive to glutamic acid decarboxylase in, 88, 93  
role in mediation of neurotoxic effects, 557  
in schizophrenia, 595–597
- GABA receptors  
antagonists, 572  
in limbic thalamus, 92–95  
role in NMDA neurotoxicity, 568
- GABA<sub>A</sub> receptors, 53–55, 93, 94, 569  
changes in  
in Alzheimer’s disease, 303  
in schizophrenia, 591–592
- GABA<sub>B</sub> receptors, 53–55, 94–95
- Gastric motility and secretion, anterior cingulate cortex role in, 214
- Genetic factors, role in neuron development, 151
- Gilles de la Tourette syndrome, 537, 543–545  
brain areas involved in, 544–545
- Glutamate  
as excitatory amino acid, 557–558  
neurotoxic properties of, 558–559, 562  
as thalamocortical transmitter, 239, 558
- Glutamate receptors  
in cingulate cortex, 559–560  
in limbic thalamus, 96–97
- Glutamatergic/GABAergic feed-forward inhibitory inputs, to cingulate cortex from hippocampal formation, 237–239
- Glutamatergic system  
possible role in psychotic diseases, 551–562
- in posterior cingulate cortex, 551–562
- Glycine, as inhibitory neurotransmitter in CNS, 95
- Glycine receptors, in limbic thalamus, 95
- Great limbic lobe, 1
- Gyrus forniciatus, 24
- Hallucinations, in schizophrenia, 243
- Head-direction cells, in retrosplenial cortex, 144
- Heart period, definition and use of, 391–392
- Heat shock protein, abnormal expression following NMDA receptor antagonists, 557, 563–565
- Heteroreceptors  
definition of, 135  
for norepinephrine, 293  
for serotonin, 287–290
- Hindlimb representations in cingulate motor areas, 422–423
- Hippocampal formation, 71  
Alzheimer’s disease symptoms in, 608  
area 29 connections to, 472–473  
contributions to limbic thalamic training-induced neuronal activity, 503–512  
damage effects on, 7, 462, 468–469, 546  
functional connections with anterodorsal nucleus, 515  
glutamatergic afferents and efferents of, 558  
glutamatergic/GABAergic feed-forward inhibitory inputs to cingulate cortex, 237–239
- NMDA receptors in, 559  
projections to cingulate cortex, 224–248, 254  
functional implications, 241–244  
integration with other CNS inputs, 235–237  
neurotensin in, 240  
reciprocal nature, 234  
thalamic connection role, 144–145  
role in spatial processing, 462–463, 474–476  
sensory experience and, 6  
structure, 608

- Hippocampothalamic pathway, 79
- Histaminergic fibers, in limbic thalamus, 85
- Human cingulate cortex, 527–556  
  calcium-binding proteins in, 190–193, 194–195, 197  
  cytoarchitecture, 189–190  
  electrical stimulation, 527–529  
  gross morphology, 21, 32, 34, 36  
  role in memory, 546–548  
  schizophrenia studies on, 588–598  
  surgical lesions, 435
- Huntington's disease  
  calcium-binding proteins in, 201  
  neuropathology, 582, 589  
  possible excitotoxin role in, 562
- 5-Hydroxytryptamine. *See Serotonin*
- Hypoglycemia, possible excitotoxin role in, 562
- Hypothalamus, lesions of, in conditioned bradycardia studies, 394
- Hypoxia, possible excitotoxin role in, 562
- Indifference, with cingulate lesions, 537
- Indusium griseum, 37, 613
- Infarcts, of anterior cingulate gyrus, 435
- Inferior parietal region, connections with cingulate cortex and presubiculum, 587
- Inferior frontal arteries, anterior, middle, and posterior, 24
- Information processing, in limbic thalamus, 105–107
- Infralimbic cortex  
  connections, 207–211  
  cytoarchitecture, 25  
  functions, 211–216
- Inhibitory neurotransmission, markers of, 92–97
- Insula, cingulate cortex connections of, 264
- Internal frontal artery, middle, 24
- Internal parietal artery, 24
- Interneurons, losses in schizophrenic cingulate cortex, 590–592
- Interoceptive agnosia, 219
- Interpersonal behavior, in schizophrenia, 586
- Intracranial self-stimulation, use in reinforcement pathway studies, 446–454
- Intralaminar thalamic nuclei  
  afferent innervation, 82–83  
  cytoarchitecture, 77–78  
  role in pain perception, 317–323  
  synaptology, 91–92
- Ischemia, possible excitotoxin role in, 562
- Isolation call, characteristics, 10
- James-Lange theory of emotion, 407
- Kainate receptors, 559  
  in brain areas, 560  
  characteristics of, 561
- Ketamine, neurotoxic side effects of, 562, 568
- Korsakoff's syndrome, 548  
  mediodorsal nucleus lesions in, 106
- Lateral pain system, 314, 315–317
- Lateral posterior-pulvinar complex, 72
- Laterodorsal nucleus, 72  
  afferent innervation, 79  
  in Alzheimer's disease, 610  
  connection with visual cortical regions, 72143–144  
  cytoarchitecture, 73, 125–127, 609–610  
  projections to retrosplenial cortex, 128–129
- Lateroposterior nucleus, anatomy, 127
- Laughter, clinical findings on, 10–11
- Layer I  
  calcium-binding protein-containing fibers in, 198–199  
  comparison with layer IV, 104–105  
  composition, 48–49  
  GABA<sub>A</sub> receptors, 49  
  interneurons, 48–49  
  limbic thalamocortical projections to, 19–20  
  three divisions of, 48–49
- Layer II, neuronal aggregates, 26, 124–131
- Learning and memory, 443–523.  
*See also* Avoidance learning; Spatial memory; Visuospatial processing
- age effects on, 137–139  
  cingulate cortex role in, human memory, 546–548  
  eyeblink-conditioned response to, 385–386  
  hippocampus role in, 144, 241–242, 243, 251, 252, 474–476  
  limbic thalamic role in, 478–479  
  mamillothalamic pathway role in, 86  
  parietal cortex role in, 263–264  
  peripheral attention task in, 375  
  possible NMDA receptor role in, 571–572  
  posterior cingulate cortex role in, 366–380, 461–477  
  in retrosplenial amnesia, 547–548  
  self-referenced, 7  
  training-induced modulation of, 384–386
- Lesions, of cingulate cortex, 527 in humans, 534–539
- Lesion studies of  
  anterior cingulate cortex, 450, 583  
  avoidance learning, 478–479, 480  
  cingulate gyrus, 434–435  
  drug self-administration, 454–455  
  glutamate neurotoxicity, 558  
  reinforced behaviors, 446  
  training-induced neuronal activity, 485–488
- Limbic cortex, 71. *See also* Cingulate cortex  
  allocortex, 3  
  distinctive features, 2–3  
  self-stimulation studies on, 447–448
- Limbic lobe, 5
- Limbic system  
  Alzheimer's disease and circuitry in, 606–626  
  anterior cingulate cortex and, 355  
  cingulate cortex role in, 1–15  
  definitions of, 1, 4, 71  
  in disease, 557–580  
  epilepsy and, 6  
  evolution, 8  
  functions  
    autonomic and sensorimotor, 311–441  
    in emotion, 5–6, 7  
    in olfaction, 5–6

- interactions with cingulate cortex, 208–209, 251–252
- limbic cortex, 1, 3
- posterior cingulate cortex and, 351
- subdivisions, 8
- temporocingulate relationships with, 278
- visual system interaction with, 143–144
- Limbic-system-associated membrane protein, 4, 97, 152–156, 174, 175
- Limbic thalamus, 8
- afferent innervation, 78–92
  - Alzheimer's disease symptoms in, 609–610
  - chemoarchitecture, 78–92
  - cingulate cortex projections to, 78–79
  - conditioned stimulus probability studies on, 497–498
  - cytoarchitecture, 125–127
  - definition, 71, 478
  - electrical stimulation of, 388–389
  - “fingerprint” for components of, 107–108
  - function in learning and memory, 478–479, 548–549
  - information processing in, 105–107
  - lesion studies on, 397–401
  - monoaminergic innervation and
    - monoamine receptors, 84–85  - neuronal changes during classical heart-rate conditioning, 401–403
  - nuclei, 72
  - possible chemical marker for cell subsets in, 96–98
  - projections to cingulate cortex, 235–240, 239–240
  - retrosplenial cortex connections with, 123–150
  - structure, organization, and connections, 71–122
  - synaptology of, 89–92
  - thalamic reticular nucleus and, 87–88
  - as “thalamus in the thalamus,” 108–109
  - training-induced neuronal activity in, 50, 498–503, 500–503, 508–512
- Limb movements, cingulate sulcus neurons related to, 432–433
- Local circuit neurons
- development in cingulate cortex, 161–162
  - in limbic thalamus, 88–89
- Mamillary nuclei
- Alzheimer's disease symptoms in, 608–609
  - nomenclature of, 608–609
- Mamillothalamic tract, 73, 86
- projections to thalamus, 79
- Mapping studies
- of self-stimulation sites, 448
  - of spatial memory, 476
- Maternal care
- lack of, in schizophrenia, 586
  - limbic system role in, 11–13
  - thalamocingulate division role in, 8, 9
- Medial lateral posterior nuclei-pulvinar complex, afferent innervation, 81
- Medial pain system
- anterior cingulate cortex role in, 313–344
  - connection model of, 336–338
  - definition of, 314
- Medial pulvinar
- afferent innervation, 81
  - connections with cingulate cortex, 78
  - synaptology, 91
- Medial temporal area, of humans, schizophrenia studies on, 588–589
- Medial thalamic neurons
- nociceptor-evoked activity and, 329–330
  - projections to anterior cingulate cortex, 320–323
  - projections to periaqueductal gray, 319–320
- Medial wall of hemisphere, reconstruction, 415–417
- Median raphe nucleus, projections of, 25
- Mediodorsal nucleus, 72
- afferent innervation, 80–81
  - cytoarchitecture, 74–75, 77
  - input to anterior cingulate cortex, 207–208
  - role in memory, 106, 107
  - synaptology, 90–91
- Memory. *See* Learning and memory
- Mesial frontal seizures, 532–534
- Mesocortex, 3
- Mesopontine tegmentum, projections to limbic thalamus, 86
- Metabolic mapping studies of cocaine reinforcement, 455–456
- of cortical involvement in reinforcement, 452–454
- Methamphetamine toxicity, NMDA antagonist effect on, 562
- N*-Methyl-D-aspartate. *See* NMDA
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity, NMDA antagonist effect on, 562
- Microenvironment, of developing cells, 151
- Midline nuclei
- afferent innervation, 83–84
  - cytoarchitecture, 76–77
  - role in pain perception, 317–323
  - synaptology, 91–92
- Midline visceromotor cortex, cingulate cortex and, 360
- Milk ejection, from stimulation of paragenual cortex, 12
- MK-801
- induction of *c-fos* protein by, 572
  - neurotoxic side effects of, 562, 567
- Monkey
- calcium-binding proteins in cingulate cortex of, 185–189, 194–195, 197
  - cingulate cortex, 32–34, 152, 361
  - connections of, 249–284
  - lesions, 535
  - posterior cingulate cortex, learning and memory studies, 366–380
- Monoamine afferents, development in cingulate cortex, 163
- Monoamine receptors, of limbic thalamus, 84–85
- Monoaminergic innervation of cingulate cortex, 285–310
- of limbic thalamus, 84–85
- Monoaminergic regulation
- of afferents to cingulate cortex, 296–297
  - of area 24 motor functions, 297–298
  - of cingulate cortex efferent projections, 297

- possible role in mood and anxiety disorders, 599
- Monoamines**  
in cingulate cortex, structural overview, 295–296  
role in behavioral arousal, 298–299
- Motor activity**  
initiation and activation of, 542–543  
posterior cingulate cortex role in, 362
- Motor areas**, of cingulate cortex, 276, 415–441
- Motor control system**  
area 24 role in, 297–298  
cingulate cortex role in, 331  
thalamus role in, 105–106
- Motor neuron disease**, cysteine metabolism disturbance in, 575
- Motor priming**, 516–517
- Motor system**, cingulate cortex connections of, 270–276
- m<sub>2</sub> receptors**  
in cingulate cortex, 296  
in thalamocortical axons, 137
- μ receptors**  
in cingulate cortex, 296  
in limbic thalamus, 85–86  
in thalamocortical axons, 136–137
- Muscarinic receptors**, 55–56  
activation of, 567  
of limbic thalamus, 87  
somatodendritic, 58–60  
in thalamocortical axons, 133, 135–136
- Muscimol**, receptor binding of, in Alzheimer's disease, 62
- Myelination**, of normal brain, 598
- Negative patterning discrimination**, in studies of spatial memory, 475
- Neglect**, following cingulate lesions, 540–542
- Neurodegenerative disorders**. *See also* Alzheimer's disease  
excitoxin role in, 562
- Neuroendocrine regulation**, anterior cingulate cortex role in, 214
- Neurofibrillary tangles** in Alzheimer's disease  
entorhinal cortex, 618, 621
- hippocampal formation, 608  
limbic thalamus, 610  
mamillary body, 608  
presubiculum region, 617  
supracallosal cortex and retrosplenial region, 615–616
- Neurolethyism**, possible excitotoxin role in, 562
- Neurological diseases**, hippocampal-to-cingulate cortex projection role in, 242–244
- Neuronal death**, in cingulate cortex, 172–173
- Neuronogenesis**, in cingulate cortex, 152–162
- Neurons**  
of cingulate cortex, 19–70  
of posterior cingulate cortex  
absence of delay-period firing, 377  
in visuospatial cognition studies, 366–380  
structure, connections, and development, 17–310
- Neuropeptide Y**, thalamic fibers containing, 85
- Neuropil threads**, appearance in Alzheimer's disease, 607, 609, 610
- Neurotensin**, in hippocampal formation inputs to cingulate cortex, 240
- Neurotensin receptors**  
in area 29b of granular retrosplenial cortex, 27–28, 29  
somatodendritic, 56–58  
in thalamocortical axons, 136–137
- Neurotransmitters**  
in corticothalamic control of autonomic function, 404–405, 558  
in limbic thalamus, 108
- Neurotrophin-3**  
expression in cingulate cortex, 27  
transient expression in cingulate cortex, 175
- Nicotinic receptors**  
of limbic thalamus, 87  
in thalamocortical axons, 133, 135–136
- Nitric oxide**, possible acitivity in limbic thalamus, 98
- NMDA receptors**, 557, 559  
antagonists, 557, 559  
abnormal heat shock protein induction by, 557, 563–565
- efficacy in preventing neurodegenerative conditions, 562  
neurotoxic side effects, 562–563, 569–571  
role in schizophrenia, 557  
characteristics of, 560–561  
in limbic thalamus, 95, 96, 98  
possible role in memory, 571–572  
in posterior cingulate cortex, suppression, 573–574
- Nociceptive neurons**  
in area 24b, 321–323, 325–330, 336, 337  
laminar position of, 328–329  
receptive field properties of, 326–328
- Nonpyramidal neurons**. *See also*  
Calcium-binding proteins  
bipolar type, 44  
bitufted type, 44, 45  
“chandelier” axonal morphology, 44  
GABAergic, 48  
interlaminar inhibitory circuits of, 47  
of layer I, 48  
morphology, 44–47  
multipolar type, 44  
with skirted dendrites, 44, 45–47  
small and large multipolar types, 48–49
- Noradrenergic system**  
in cingulate cortex, 290–294  
development in cingulate cortex, 163–164  
modulation of training-induced neuronal activity, 506–508  
role in depression, 301–302  
thalamic afferents, 84
- Norepinephrine**  
function in cingulate cortex and limbic system, 285–286  
role in behavioral arousal, 298–299
- Noxious stimuli**, cholinergic connections and avoidance of, 334–336
- Nucleus ambiguus**, anterior cingulate cortex projections to, 382
- Nucleus reunions**  
in Alzheimer's disease, 610  
anatomy, 609–610
- Nucleus submedius**, linkage to cingulate cortex, 101–102

- Obsessive-compulsive disorder,** cingulate cortex lesions related to improvement of, 535, 537–538, 545
- Ocular subregion** of anterior cingulate cortex, 354–355, 359–360 of posterior cingulate cortex, 350–351, 359–360
- Oculomotor system**, in studies of posterior cingulate cortex, 355–359, 367–368
- Olfaction**, limbic system role in, 4–5
- Olivopontocerebellar degeneration**, possible excitotoxin role in, 562
- Opioid receptors** in cingulate cortex, 10 in limbic thalamus, 85–86 regulation of cingulate pyramidal neurons by, 332–334 in thalamocortical axons, 136–137
- Opioids**, thalamic fibers containing, 85
- Orbital-position signal**, in posterior cingulate cortex neurons, 376
- Orbitofrontal artery**, 24
- Orbitofrontal connections**, of cingulate cortex, 260–261
- Orientation response**, cingulate cortex role in, 298–300
- Orienting reflex**, definition and use of, 392
- OX7-saporin**, use in receptor localization, 57
- Oxytocin** cerebral receptors for, 12, 27 effects of injection into paraventricular nucleus, 12 transient expression in cingulate cortex, 174–175
- Pain.** *See also* Lateral pain system; Medial pain system cingulate cortex lesions in abatement of, 535, 537 cingulate cortex role in, 285, 313–344 limbic system role in, 105, 208
- Panic disorder**, in depressed individuals, 599
- Parabrachial nucleus**, cholinergic neurons in, 335
- Paragenual cortex**, role in milk ejection, 12
- Parahippocampal cortex**, cingulate cortex connections with, 254–255
- Parahippocampal gyrus**, visual, auditory, and somatic connections with, 6–7
- Parasubicular neurons**, 142
- Paraventricular nucleus**, anatomy, 609–610
- Parietal cortex** cingulate cortex connections of, 263–264 inputs to cingulate motor areas from, 426 sensory-, movement-, and memory-related neuronal response in, 263–264
- Parieto-occipital artery**, 24
- Parkinsonism**, possible excitotoxin role in, 562
- Parkinson's disease**, cysteine metabolism disturbance in, 575
- Parvalbumin** biochemistry and distribution, 181–182 in cingulate cortex, 184–195, 198 in limbic thalamus, 97–98 neuronal localization, 182–184
- PCP** CNS binding sites for, 560, 567 neurotoxic side effects of, 562, 568, 573 as NMDA receptor antagonist, 559, 562, 572
- Pentobarbital**, use to prevent ketamine side effects, 568
- Peptide receptors**, in limbic thalamus, 85–86
- Peptidergic innervation**, of limbic thalamus, 85
- Periaqueductal gray** anterior cingulate cortex projections to, 314, 331 reciprocal medial thalamic connections of, 319–320 role in noxious stimuli responses, 319, 331
- Pericallosal artery**, 23 branches of, 24
- Peripheral theory of emotion**, 217–218
- Personality** cerebral areas responsible for, 606 changes in Alzheimer's disease, 606, 621 definition of, 583 evolution of, 600
- Phencyclidine.** *See* PCP
- Pick's disease**, calcium-binding proteins in, 201
- Pirenzepine**, receptor binding by, 55, 59, 63, 135–136
- Place cells** in hippocampal formation, 241 in retrosplenial cortex, 144
- Playful behavior**, cingulate cortex role in, 9
- Posterior cerebral artery**, 24
- Posterior cingulate cortex** anatomical organization, 345–351 contributions to behavioral control and spatial memory, 360–361 learning and memory, 366–380, 461–477 glutamatergic system in, 551–562 limbic system and, 351 of monkey, linkage to other CNS areas, 374–377 NMDA antagonist effect on, 562–563 orbital-position neurons of, 376 single-neuron responses in, 355–359 somatic, ocular, and complex subregions of, 350–351, 359–360 subdivisions, 347–348 subregional differences in cortical input, 348–349 subregional differences in thalamic input, 349–350 training-induced neuronal studies of, 483–498 visuospatial processing in, 377–378
- Posterior circuit**, of thalamocortical system, 479
- Postsaccadic neuronal activity**, 368–371, 376
- Postsubicicular neurons**, 141–142
- Precallosal artery**, 23
- Precuneal artery**, 24
- Prefrontal control**, of autonomic function, 381–414
- Prefrontal cortex** inputs to cingulate motor areas from, 426 lesions of, in conditioned bradycardia studies, 394 neuronal changes in, during training, 396–397 topography, 448–450
- Prelimbic cortex.** *See also* Area 25

- cytoarchitecture, 25
- Presubiculum region  
in Alzheimer's disease, 617  
anatomy, 616  
inferior parietal region connections with, 587  
neurons, 142
- Primates. *See also* Human cingulate cortex; Monkey calcium-binding proteins in cingulate cortex of, 193–194 cingulate connections in brains of, 249–252
- Projection neurons  
development in cingulate cortex, 162  
in limbic thalamus, 88–89
- Propylbenzilylcholine mustard, binding by pyramidal and multipolar neurons, 55
- Proximal arm representations, of cingulate motor areas, 423
- Psychiatric disorders. *See also* Alzheimer's disease; Schizophrenia  
cingulate cortex role in, 581–605  
overlapping behavioral abnormalities in, 598–600
- Psychotic diseases, possible glutamatergic system role in, 572–574
- Pulvinar, 72  
cytoarchitecture, 78  
synaptology, 91
- Pyramidal neurons  
of cingulate cortex, opioid receptor regulation, 332–334  
dendritic bundles, 49  
dendritic clusters, 49  
dendritic trees, 37  
development in cingulate cortex, 162  
distal apical tufts, 41, 44  
extraverted, 38  
extraverted dendritic trees, 37  
of fasciolate and cingulate gyri, 37  
fusiform, 37, 38–39, 40  
corticocortical connections, 39
- GABAergic projections to layer Ia of, 44
- interlaminar excitatory circuits, 47–48
- layer VI type, 42, 43
- morphology of, 39–44
- as site of Alzheimer neurofibrillary tangles, 607, 608
- small, medium, and large, 39, 41, 42  
in trisynaptic local circuitry, 571
- Psychomotor epilepsy, 6
- Quisqualate receptors  
characteristics of, 961  
in limbic thalamus, 96
- Rabbit  
avoidance learning in, 479–480  
cingulate cortex structure, 25, 28  
nociceptive neuron studies on, 325–326
- Rat  
anterior cingulate cortex, 206–222  
calcium-binding proteins in cingulate cortex of, 184, 193–194  
cingulate cortex  
development, 152–170  
structure, 25, 152, 224–248, 361  
synaptic integration in, 25–239  
thalamus-retrosplenial cortex  
interconnections in, 123–150  
visceral control functions in, 206–218
- Receptive field properties  
of neurons in Pf, centrolateral, and submedial nuclei, 318–319  
of nociceptive neurons, 326–328
- Receptor localization, dissociation and experimental approaches to, 51–53
- Reflexive autonomic responses, control by cingulate–prefrontal systems, 386–390
- Regular-spiking neurons, bursting neurons compared to, 42
- Reinforcement  
cortical mechanisms of, 445–460  
multiple pathways of, 457  
neural substrates of, 445–446  
processes of, 445–446
- Reticular nucleus, limbic thalamus and, 87–88
- Retrieval processes for stored information, topographic patterns in, 513–515
- Retrograde gradient, from hippocampal damage, 469–469
- Retrosplenial amnesia, 251, 547–548
- Retrosplenial cortex, 21–22, 23.  
*See also* Area 29; Area 30; Posterior cingulate cortex  
age-related changes in, 137–139  
in Alzheimer's disease, 614, 615–616  
cytoarchitecture, 27–32, 35–38, 611, 612, 613–614  
dendritic bundles in, 129–130  
dysgranular, 30–31  
effect on hippocampal role in memory and learning, 144–145  
granular, cytoarchitecture, 27–30  
granular vs. agranular regions of, 613  
limbic thalamus connections with, 123–150
- Rod-column organization, in thalamocortical system, 123–124
- Saccadic activity, of eye, 358
- Schizophrenia  
attention deficits in, 575, 584–585  
cingulate cortex role in, 581–605  
network disruption, 587–588  
cognitive abnormalities in, 586–587  
developmental excitotoxic hypothesis of, 574–575, 597  
emotional signs of, 583–584  
etiology, 573  
hippocampal-to-cingulate cortex projection role in, 242–243  
inherited factor for, 597  
interpersonal behavior deficits in, 586, 597  
maternal care lack in, 12, 586  
motivational deficits in, 585–586  
neuropathology, 581–582  
NMDA receptor role in, 557, 574–576  
normal development in, 597–598

- posterior cingulate cortex role in, 573  
studies on humans, 588–598  
symptoms of, 583–588
- Scopolamine**, as neurotoxin, 567, 568
- Seizure disorders**. *See also* Epilepsy  
hippocampal-to-cingulate cortex projection role in, 242
- Seizures**  
*c-fos* and HSP genes induction after, 565  
in human cingulate cortex, 529–534  
mesial frontal, 532–534
- Self-stimulation**  
dopamine role in, 450–451  
use in reinforcement pathway studies, 446–447
- Sensorimotor function**, 311–441
- Sensorimotor integration**, cingulate cortex role in, 345–365
- Sensory activity**. *See also* Nociceptive neurons  
in anterior cingulate cortex, 208–209  
posterior cingulate cortex role in, 362
- Sensory afferents**, of limbic thalamus, 79–80
- Separation anxiety**, in phobic individuals, 599
- Separation cry**, of mammals, 8, 9, 12, 599
- Septohippocampal projection**, cholinergic neurons in, 335
- Serotonergic afferents**, development in cingulate cortex, 165–167
- Serotonergic system**. *See also* Serotonin receptors  
in cingulate cortex, 152, 286–290  
role in depression, 301–302  
serotonin receptors of, 56–60  
thalamic afferents, 84
- Serotonin**  
function in cingulate cortex and limbic system, 285–286  
role in behavioral arousal, 298, 299
- Serotonin afferents**, in cingulate cortex, 286–287
- Serotonin receptors**  
changes in, in Alzheimer's disease, 303  
in cingulate cortex, 287–290  
postsynaptic, 289–290
- 5-HT1 receptors**
- in limbic thalamus, 84  
loss in Alzheimer's disease, 302
- 5-HT1A receptors**, in cingulate cortex, 57, 58, 289, 290, 295
- 5-HT1B receptors**  
in cingulate cortex, 57, 58, 288, 289, 296, 297  
predominance in limbic thalamus, 85  
in thalamocortical axons, 136, 137
- 5-HT1D receptors**, in cingulate cortex, 288, 289
- 5-HT2 receptors**, 84  
in cingulate cortex, 297  
loss in Alzheimer's disease, 302
- 5-HT3 receptors**, 84  
in cingulate cortex, 297
- in limbic thalamus, 84–85  
pharmacological subtypes, 287  
in thalamocortical axons, 136–137
- Skeletomotor function**, cingulate cortex role in, 415–441
- Sleep**, 86  
cerebral histamine and, 85
- Solitary nucleus**, anterior cingulate cortex projections to, 382
- Somatic subregion**  
of anterior cingulate cortex, 354–355, 359–360  
of posterior cingulate cortex, 350–351, 359–360
- Somatodendritic receptors**  
binding changes in Alzheimer's disease, 60–62  
in cingulate cortex, 51–60  
coregulation of, 58–60
- Somatosensory cortex**, role in pain perception, 316–317
- Somatostatin**  
in Alzheimer's disease, 201  
neurons immunoreactive to, in cingulate cortex, 158, 161  
thalamic fibers containing, 85
- Spatial memory**  
cingulate cortex role in, 345  
anterior and posterior areas compared, 360–361
- posterior cingulate cortex role in**, 461–477  
reference type, 463–464  
retention studies on, 466–468  
working type, 464–466
- Spatial processing**, hippocampal-cingulate cortex interaction role in, 241
- Spinal cord**  
afferents to midline and intralaminar thalamic nuclei from, 317–318  
noxious afferent coding of, 315
- Subiculum complex**  
glutamatergic afferents and efferents of, 558  
projections from, 141–142  
projections to cingulate cortex, 225–226
- Substance P**, thalamic fibers containing, 85, 86
- Substantia nigra pars compacta**, stimulation studies on, 454
- Sulfite oxidase deficiency**, possible excitotoxin role in, 562
- Superior temporal cortex**, cingulate cortex connections with, 255–257
- Supplementary motor area**, role in motor activity, 542–543, 546
- Supracallosal allocortex**  
in Alzheimer's disease, 614, 615–616  
anatomy, 37, 611, 613
- Synaptology**, of limbic thalamus, 89–92
- Tachykinin**, thalamic fibers containing, 85
- tau protein**, in Alzheimer neurofibrillary tangles, 607
- Temporal pole**, cingulate cortex connections with, 257–258
- Tenascin**, 155–156
- Thalamic inputs**, to cingulate motor areas, 425–426
- Thalamic nuclei**. *See individual names of nuclei*
- Thalamocingulate connections**, 99–105, 170–172  
organization, 102–104
- Thalamocingulate division**, of limbic system, 8
- Thalamocortical axons**, 130–137  
single distribution of, 130  
ultrastructure, 130–133
- Thalamocortical organization**, 123–125  
rod-column organization, 123–124  
topography, 127–129, 142–143
- Thalamotomy**, for pain relief, 319

- Tiletamine, neurotoxic side effects of, 562
- Tone-evoked neuronal activity, in studies of avoidance learning, 481–482
- Training-induced neuronal activity  
in anterior and posterior circuits, 483–498  
cingulate circuitry and, 50–51  
irreversibility of, 492  
origins of, 498–515  
reversibility of, 488–492  
types of, 483
- Training-stage-related peaks, functions of, 512–515
- Trauma to CNS, possible excitotoxin role in, 562
- Tuberomamillary nucleus, Alzheimer neurofibrillary tangles in, 609
- Undercut ablations, use in receptor localization, 52
- Vasoactive intestinal polypeptide, effect on cingulate cortex neurons, 158, 161
- Vasopressin, transient expression in cingulate cortex, 174–175
- Ventral anterior nucleus, 72  
afferent innervation, 81–82  
cytoarchitecture, 75–76  
synaptology, 91
- Ventral bank of cingulate sulcus, cytoarchitecture, 423–424
- Ventral posterolateral nucleus, nociceptor-derived information relay by, 315
- Ventral posteromedial nucleus, nociceptor-derived information relay by, 315
- Ventral tegmental area  
projections to cingulate cortex, 237, 239–240  
stimulation studies on, 453, 454
- Ventral thalamic nuclei, role in pain perception, 315–316
- Ventromedial nucleus, 72  
afferent innervation, 81–82  
cytoarchitecture, 75–76  
synaptology, 91
- Vertical axons, increased in schizophrenic anterior cingulate cortex, 592–594
- Visceral control, anterior cingulate cortex role in, 211–215
- Visceral motor cortex, 215–217
- Visual reaference, effects on posterior cingulate neurons, 371–372
- Visual stimuli, phasic responses to, 374
- Visual system  
limbic system interaction with, 143–144  
in studies of posterior cingulate cortex, 355–359, 367–368, 374, 376
- Visuospatial processing, in posterior cingulate cortex, 377–378
- Vocalization  
cingulate cortex role in, 331–332, 434, 543  
inappropriate, from cingulotomy, 536
- Wernicke-Korsakoff syndrome, 548
- NMDA antagonist effect on, 562